logo

Adma Biologics, Inc. (ADMA)



Trade ADMA now with
  Date
  Headline
2/6/2020 8:52:07 PM ADMA Biologics Prices Underwritten Public Offering Of 23.50 Mln Shares At $3.50/shr
1/9/2020 7:11:32 AM ADMA Biologics Q4 Preliminary Total Revenues $11.9 Mln, Up 193%
1/7/2020 7:09:20 AM ADMA Biologics Enters Manufacturing And Supply Deal To Produce And Sell Plasma-Derived Intermediate Fractions
11/4/2019 7:10:14 AM ADMA Biologics Announces Acceptance To The Plasma Protein Therapeutics Association
10/21/2019 8:17:44 AM ADMA Biologics Announces First Commercial Sales Of ASCENIV
10/17/2019 7:40:42 AM ADMA Biologics Announces Publication Of Article Describing Manufacturing Process Optimization For BIVIGAM And ASCENIV
8/22/2019 7:51:01 AM ADMA Biologics Announces Commercial Relaunch And Its First Commercial Sales Of BIVIGAM
7/8/2019 8:33:54 AM ADMA Biologics Receives FDA Approval For License Transfers For BIVIGAM And Nabi-HB
5/10/2019 7:10:57 AM ADMA Biologics: FDA Approves Prior Approval Supplement For BIVIGAM; Says It Will Commence Commercial Sales Of BIVIGAM
4/4/2019 8:04:37 AM WBB Securities Raises ADMA BIOLOGICS, INC. (ADMA) To Buy From Speculative Buy With $11.50 Price Target
1/7/2019 7:20:55 AM ADMA Biologics Submits Response And Provides Supplemental Information To FDA For BIVIGAM CRL
12/17/2018 7:02:43 AM WBB Securities Starts ADMA BIOLOGICS, INC. (ADMA) At Speculative Buy With $9 Price Target
10/17/2018 7:09:20 AM ADMA Biologics Receives PDUFA Date Of April 2, 2019 For RI-002
  
 
>